深入观察 Rho 相关蛋白激酶抑制剂滴眼剂治疗 Fuchs 内皮角膜营养不良的临床疗效。
A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
机构信息
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Ophthalmology, New York University (NYU), New York, NY; and.
出版信息
Cornea. 2021 Oct 1;40(10):1225-1228. doi: 10.1097/ICO.0000000000002642.
The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.
目前对于 Rho 相关蛋白激酶（ROCK）抑制剂治疗 Fuchs 内皮角膜营养不良的临床疗效的理解进行了总结，以明确“超适应证”ROCK 抑制剂滴眼应用是否合适。ROCK 抑制剂滴眼剂最终可能被视为伴有急性角膜内皮缺损的 Fuchs 内皮角膜营养不良患者的一种前沿治疗方法。
Zotero 插件